SCHEMBL27157744

SCHEMBL27157744

Nc1ncc(-c2ccc(N3CCC(O)CC3)cc2)nc1Cl

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 2/20 0.45
▸ NEK2 P51955 4/20 0.44
▸ ADK P55263 1/20 0.44
▸ CDK1 P06493 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ ATR Q13535 2/20 0.43
▸ PTPN11 Q06124 1/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ ACVR1 Q04771 4/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ DHFR P00374 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ PRKCA P17252 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ PRKCQ Q04759 1/20 0.38
▸ PIM2 Q9P1W9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27157799 0.83 ADK (0.62) CHEK1ADKATRJAK2JAK3
SCHEMBL27157775 0.82 CHEK1 (0.61) CHEK1ADKJAK2KDM4EMAPT
SCHEMBL27157531 0.79 HRH3 (0.48) CHEK1ADKACVR1KDM4EDHFR
SCHEMBL27157857 0.77 SYK (0.41) CHEK1NEK2ADKATRJAK2
SCHEMBL27157883 0.77 SYK (0.41) CHEK1NEK2ADKATRJAK2
SCHEMBL27157872 0.77 SYK (0.41) CHEK1NEK2ADKATRJAK2
SCHEMBL2323120 0.73 ROCK2 (0.65) NEK2
SCHEMBL27157946 0.72 ADK (0.43) CHEK1ADKATRACVR1
SCHEMBL27157957 0.72 ADK (0.43) CHEK1ADKATRACVR1
SCHEMBL27157640 0.72 ADK (0.43) CHEK1ADKATRACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317723-A1 SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-09-26 — — US disclosed
EP-4330252-A1 SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) Ontario Institute for Cancer Research (OICR) (CA) 2024-03-06 — — EP disclosed
CN-117597340-A Substituted amino-aza-heteroaryl compounds as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) 安大略省癌症研究所(OICR) 2024-02-23 — — CN disclosed
WO-2022226666-A1 SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317723-A1 SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) DCK, CMPK1, PHKA1 CHEK1 256/4885NEK2 46/4885ADK 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback